---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000118"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:17:37.481172+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiora Q2 net loss $2.6M; ABACUS phase 1b shows KIO-301 proof-of-concept in retinitis pigmentosa

## Summary
- Net loss $2.6M in Q2 2023 vs $2.4M Q2 2022; cash $8.0M at quarter end.
- Preliminary ABACUS data: KIO-301 safe/tolerable with positive vision impact; topline results expected Q4 2023.
- Sharpened focus on rare retinal diseases; KIO-301 trials to expand to choroideremia and Stargardt's disease.
- Shifted resources from KIO-101 (ocular RA) to KIO-104 (posterior uveitis); seeking partnerships for anterior segment programs.
- Raised $6.3M funding extending runway to May 2024; received $1.2M in R&D tax credits from Australia and Austria.

## SEC filing metadata
- accession: 0001372514-23-000118
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/0001372514-23-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/kprx-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000118
- JSON: https://secwatch.observer/filing/0001372514-23-000118.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000118.txt

## Key facts
- Earnings Releases
  KIORA PHARMACEUTICALS INC reported second quarter 2023 results: net income Net loss was $2.6 million for the second quarter of 2023.
  - Period: second quarter 2023
  - Net income: Net loss was $2.6 million for the second quarter of 2023
  - Result: reported results
  source text: On August 8, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended June 30, 2023 and an update on clinical development progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000118/0001372514-23-000118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.